Milestone Pharmaceuticals (MIST)
NASDAQ:MIST
Want to see MIST full AI Analyst Report?
Earnings Data
Report Date
Aug 12, 2026Before Open (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
-0.19Last Year’s EPS
-0.2Same Quarter Last Year
Strong Buy
Based on 4 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call presents a predominantly positive early-launch narrative: Milestone executed a rapid launch, secured an important Express Scripts formulary placement, achieved early prescriber breadth (≈400 writers) and initiated a Phase III AFib-RVR program, while ending the quarter with a strengthened cash position (~$184M) and a planned, ROI-driven commercial strategy. Offsetting these positives are very small product revenues ($0.2M), elevated launch-driven commercial spend (+51.9% YoY), an increased quarterly net loss (~+25.5% YoY) and continued operating cash burn (~$23.7M in Q1). Coverage remains limited (~25% commercial) and scale/refill dynamics are in the earliest stages, so near-term sales will likely remain modest until broader payer coverage, patient activation and increased promotional frequency deliver deeper adoption.Company Guidance
Successful and Fast Commercial Launch of CARDAMYST
CARDAMYST (etripamil) launched within ~2 months of FDA approval (approved Dec 12, 2025; available in retail by end of Jan 2026). National sales force (~60 reps) deployed mid-February and promotion began in mid-February.
Early Prescription and Prescriber Traction
Approximately 600 total prescriptions captured through end of April (Feb ~100, Mar ~200 → ~300 in first partial quarter; Apr ~300). Prescriptions written by >400 unique HCPs for ~560 unique patients. Company reports multi-prescriber breadth early (≈400 writers) after engaging ~1/3 of the ~10,000 target prescribers.
Major Payer/Formulary Win — Express Scripts
Express Scripts added CARDAMYST to its commercial national formularies (announced Mar 31), giving an estimated ~25% of commercially insured lives 'quality coverage' (major early validation of payer acceptance).
Positive HCP and Patient Feedback
Consistent favorable reception from cardiologists, EPs, nurses and APPs; early patient anecdotes describe effective event management and improved sense of preparedness even before use, supporting product value proposition.
Initiation of Phase III AFib-RVR Program (ReVeRa-301)
Phase III registration trial for AFib with rapid ventricular rate (ReVeRa-301) initiated; trial will use same 70 mg dose/regimen and outpatient self-administration model. First patient enrollment expected in H2 2026; study powered ~90% with ~150–200 events and is expected to take ~2 years from first patient to data.
Strong Cash Position and Runway
Cash, cash equivalents and short-term investments of ~$184M as of Mar 31, 2026 vs $106M at Dec 31, 2025 (increase of ~$78M, ~+74%). Company states runway to support CARDAMYST launch and ReVeRa-301 into the second half of 2027. Increase primarily from $75M RTW payment plus ~$19M net proceeds from ATM and warrant exercises.
Disciplined Commercial Signals and Strategy
Early prescribing often after 1–2 rep interactions, showing strong promotional response. Management focusing on staged patient activation and payer coverage expansion before larger DTC spend; targeting ROI-driven expansion of promotional activities and possible future sales force growth when coverage and promotional response justify it.
MIST Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
MIST Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 13, 2026 | $1.90 | $1.72 | -9.47% |
Mar 20, 2026 | $1.70 | $1.36 | -20.00% |
Nov 12, 2025 | $1.91 | $1.93 | +1.05% |
Aug 12, 2025 | $1.55 | $1.66 | +7.10% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Milestone Pharmaceuticals (MIST) report earnings?
Milestone Pharmaceuticals (MIST) is schdueled to report earning on Aug 12, 2026, Before Open (Confirmed).
What is Milestone Pharmaceuticals (MIST) earnings time?
Milestone Pharmaceuticals (MIST) earnings time is at Aug 12, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is MIST EPS forecast?
MIST EPS forecast for the fiscal quarter 2026 (Q2) is -0.19.